- Uveal Melanoma Guideline
Uveal Melanoma Guideline
The Uveal Melanoma Guideline is currently being updated under the chairmanship of Dr Paul Nathan.
These Guidelines will be developed in accordance with the Melanoma Focus Guideline Development Methodology Manual. The methods have been accredited by NICE as complying with their AGREE II criteria for the rigorous development of evidence-based guidelines.
“Uveal melanoma is now classified as a distinct disease entity (rather than a different form of cutaneous melanoma) and has been granted ‘orphan status’ which means that there are some incentives to encourage new medicines to be developed. It is an exciting time for uveal melanoma as there are new treatments in development which will hopefully be available outside of clinical trials soon.”
Dr Paul Nathan, Trustee (consultant medical oncologist, Mount Vernon Cancer Centre)
There is a need for a specialist guideline on uveal (ocular) melanoma as this form of the disease is a very rare condition which is managed differently from other melanomas. Comprehensive guidance on this subject was developed for the first time in 2015. While much of the guideline is still current, the following sections are being updated or added:
- molecular pathology and features
- prognostic markers
- loco-regional management of hepatic predominant disease
- management of metastatic disease
- adjuvant radiation therapy
- support of patients
Members of the Uveal Melanoma Guideline Development Group:
- Dr Paul Nathan Chairman Medical Oncologist
- Prof Sarah Coupland Pathologist
- Dr Rachel Lewis Clinical Oncologist
- Dr Sachin Modi Interventional Radiologist
- Dr Sukaina Rashid Medical Oncologist
- Dr Joe Sacco Medical oncologist
- Dr Karen Sisley Senior Lecturer
- Dr Samra Turajlic Medical Oncologist
- Dr Matthew Wheater Medical Oncologist
- Ms Audrey Woraker Patient Representative
- Ms Nancy Turnbull, Project Manager
Note: The Uveal Melanoma Guideline is currently being updated under the chairmanship of Dr Paul Nathan. Any queries about this process should be directed to firstname.lastname@example.org.
The original guideline has been published in The European Journal of Cancer (EJC) (Eur J Cancer 2015 Nov;51(16):2404-12) with open access. Follow this link for the PubMed abstract.
Click here for the original guideline
- Press Release: Melanoma Focus—-
- News Article by NICE: ‘NICE grants seal of approval to guidelines on rare form of cancer’
- Uveal Melanoma National Guideline Report Summary
- Lay Summary of information for patients, carers and public
- Resources Page: Full Report & supporting documents